
Novartis’ Afinitor (everolimus) will be removed from the Cancer Drugs Fund list when NHS England announces which drugs it can …

Amgen and Novartis have launched new licensing agreements with biotech companies that they hope will lead to the development of …

Preliminary results from a Phase II trial of Astellas’ Xtandi (enzalutamide) show positive benefits for the prostate cancer drug when …

The European Federation of Pharmaceutical Industries and Associations (EFPIA) has named Novartis chief executive Joe Jimenez as its new president. …

An investigational biosimilar by Novartis’ generic pharma arm Sandoz has been found to have comparable safety and efficacy readings to …

Merck has purchased US antibiotics maker Cubist in a deal valued at $9.5 billion. The acquisition values Cubist at around …

The Italian drugs safety agency has cleared the Novartis influenza vaccine Fluad, after an investigation found the vaccine was not …
Novartis’ multiple myeloma treatment Farydak has been given an extended review by the FDA after its future seemed in jeopardy …
Novartis suffered a major disappointment with the negative FDA panel vote for multiple myeloma candidate Farydak earlier this month, but …
Novartis has been asked in draft guidance to give NICE more information before the watchdog can recommend its veteran asthma …

Novartis is to present data from four pivotal Phase III trials in two debilitating inflammatory diseases at the American College …
UK-based biotech Oxford BioMedica is working with Novartis in a transformational deal for the firm worth $90 million to develop …

Swiss pharma giant Novartis has announced three of its executives are to leave the firm following deals with Lilly and …
The first TB medication to be approved in four decades and the first ever vaccine to treat invasive meningococcal disease …
Novartis pipped Bayer and its big pharma rivals Boehringer, Genentech, GSK and Sanofi to the post in receiving the first …